Page 27 - GTM-3-1

Global Translational Medicine Role of HTS in cancer therapeutics

random integration after transfection of chicken B cell throughput DNA damage detection platform for genotoxic
lines. Cell. 1991;67(1):179‑188. compound screening. Sci Rep. 2018;8(1):2771.
doi: 10.1016/0092‑8674(91)90581‑i doi: 10.1038/s41598‑018‑20995‑w
113. Yamazoe M, Sonoda E, Hochegger H, Takeda S. Reverse 124. Gatti L, Zunino F. Overview of tumor cell chemoresistance
genetic studies of the DNA damage response in the mechanisms. Methods Mol Med. 2005;111:127‑148.
chicken B lymphocyte line DT40. DNA Repair (Amst). doi: 10.1385/1‑59259‑889‑7:127
2004;3(8‑9):1175‑1185.
125. Gottesman MM, Fojo T, Bates SE. Multidrug resistance
doi: 10.1016/j.dnarep.2004.03.039
in cancer: Role of ATP‑dependent transporters. Nat Rev
114. Walmsley RM, Tate M. The GADD45a-GFP greenscreen Cancer. 2002;2(1):48‑58.
HC assay. Methods Mol Biol. 2012;817:231‑250.
doi: 10.1038/nrc706
doi: 10.1007/978‑1‑61779‑421‑6_12
126. Gottesman MM, Ling V. The molecular basis of multidrug
115. Knight AW, Little S, Houck K, et al. Evaluation of high‑ resistance in cancer: The early years of P‑glycoprotein
throughput genotoxicity assays used in profiling the research. FEBS Lett. 2006;580(4):998‑1009.
US EPA ToxCast™ chemicals. Regul Toxicol Pharmacol. doi: 10.1016/j.febslet.2005.12.060
2009;55(2):188‑199.
127. Sharom FJ. ABC multidrug transporters: Structure,
doi: 10.1016/j.yrtph.2009.07.004
function and role in chemoresistance. Pharmacogenomics.
116. Hastwell PW, Chai LL, Roberts KJ, et al. High‑specificity 2008;9(1):105‑127.
and high-sensitivity genotoxicity assessment in a human doi: 10.2217/14622416.9.1.105
cell line: Validation of the GreenScreen HC GADD45a‑
GFP genotoxicity assay. Mutat Res. 2006;607(2):160‑175. 128. Sparreboom A, van Asperen J, Mayer U, et al. Limited oral
bioavailability and active epithelial excretion of paclitaxel
doi: 10.1016/j.mrgentox.2006.04.011
(Taxol) caused by P-glycoprotein in the intestine. Proc
117. Giuliano KA, Gough AH, Taylor DL, Vernetti LA, Natl Acad Sci U S A. 1997;94(5):2031‑2035.
Johnston PA. Early safety assessment using cellular doi: 10.1073/pnas.94.5.2031
systems biology yields insights into mechanisms of action.
J Biomol Screen. 2010;15(7):783‑797. 129. Kartner N, Riordan JR, Ling V. Cell surface P‑glycoprotein
associated with multidrug resistance in mammalian cell
doi: 10.1177/1087057110376413
lines. Science. 1983;221(4617):1285‑1288.
118. Brattain MG, Fine WD, Khaled FM, Thompson J, doi: 10.1126/science.6137059
Brattain DE. Heterogeneity of malignant cells from a human
colonic carcinoma. Cancer Res. 1981;41(5):1751‑1756. 130. Shen DW, Cardarelli C, Hwang J, et al. Multiple drug‑
resistant human KB carcinoma cells independently
119. Xing JZ, Zhu L, Gabos S, Xie L. Microelectronic cell sensor selected for high-level resistance to colchicine, adriamycin,
assay for detection of cytotoxicity and prediction of acute or vinblastine show changes in expression of specific
toxicity. Toxicol In Vitro. 2006;20(6):995‑1004. proteins. J Biol Chem. 1986;261(17):7762‑7770.
doi: 10.1016/j.tiv.2005.12.008 131. Roe M, Folkes A, Ashworth P, et al. Reversal of
120. Fox JT, Sakamuru S, Huang R, et al. High-throughput P-glycoprotein mediated multidrug resistance by novel
genotoxicity assay identifies antioxidants as inducers of anthranilamide derivatives. Bioorg Med Chem Lett.
DNA damage response and cell death. Proc Natl Acad Sci. 1999;9(4):595‑600.
2012;109(14):5423‑5428. doi: 10.1016/s0960‑894x(99)00030‑x
doi: 10.1073/pnas.1114278109 132. Dantzig AH, Shepard RL, Law KL, et al. Selectivity
121. Sikdar N, Banerjee S, Lee KY, et al. DNA damage responses of the multidrug resistance modulator, LY335979, for
by human ELG1 in S phase are important to maintain P-glycoprotein and effect on cytochrome P-450 activities.
genomic integrity. Cell Cycle. 2009;8(19):3199‑3207. J Pharmacol Exp Ther. 1999;290(2):854‑862.
doi: 10.4161/cc.8.19.9752 133. Mistry P, Stewart AJ, Dangerfield W, et al. In vitro and
in vivo reversal of P-glycoprotein-mediated multidrug
122. Scholes DT, Banerjee M, Bowen B, Curcio MJ. Multiple resistance by a novel potent modulator, XR9576. Cancer
regulators of Ty1 transposition in Saccharomyces Res. 2001;61(2):749‑758.
cerevisiae have conserved roles in genome maintenance.
Genetics. 2001;159(4):1449‑1465. 134. Bates SF, Chen C, Robey R, Kang M, Figg WD, Fojo T.
Reversal of multidrug resistance: Lessons from clinical
doi: 10.1093/genetics/159.4.1449
oncology. Novartis Found Symp. 2002;243:83‑96;
123. Sykora P, Witt KL, Revanna P, et al. Next generation high discussion 96-102, 180-185.

Volume 3 Issue 1 (2024) 19 https://doi.org/10.36922/gtm.2448